--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About SYRE20260515C50
Biological Technology
Spyre Therapeutics, Inc., was converted from a Delaware limited liability company on December 16, 2013. The company is a biotechnology company that aims to create the next generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational treatment combinations, and precision medical approaches for patient selection. Spyre's product line includes extended half-life antibodies against α4β7, TL1A and IL-23.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
